Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow

PFMCrypto Launches Revolutio ...